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Background: Somatostatin analogues (SSAs) are indicated to relieve carcinoid syndrome but seem to have
antiproliferative effects on neuroendocrine tumours (NETs). This is the first prospective study investigating tumour
stabilisation with the long-acting SSA lanreotide Autogel in patients with progressive NETs.
Methods: This was a multicentre, open-label, phase II trial conducted in 17 Spanish specialist centres. Patients with
well-differentiated NETs and radiologically confirmed progression within the previous 6 months received lanreotide
Autogel, 120 mg every 28 days over ≤92 weeks. The primary endpoint was progression-free survival (PFS). Secondary
endpoints were response rate, tumour biomarkers, symptom control, quality of life (QoL), and safety. Radiographic
imaging was assessed by a blinded central radiologist.
Results: Of 30 patients included in the efficacy and safety analyses, 40% had midgut tumours and 27% pancreatic
tumours; 63% of tumours were functioning. Median PFS time was 12.9 (95% CI: 7.9, 16.5) months, and most patients
achieved disease stabilisation (89%) or partial response (4%). No deterioration in QoL was observed. Nineteen patients
(63%) experienced treatment-related adverse events, most frequently diarrhoea and asthenia; only one treatment-
related adverse event (aerophagia) was severe.
Conclusion: Lanreotide Autogel provided effective tumour stabilisation and PFS >12 months in patients with
progressive NETs ineligible for surgery or chemotherapy, with a safety profile consistent with the pharmacology
of the class.
Trial registration: ClinicalTrials.gov Identifier NCT00326469; EU Clinical Trial Register EudraCT no 2004-002871-18.
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Somatostatin has widespread inhibitory effects on the
endocrine system due to exocrine, endocrine, paracrine
and autocrine actions; it also regulates cell proliferation
in normal and tumour tissue, through actions mediated
via five G-protein-coupled somatostatin receptors [1].
Both forms of native somatostatin (−14 and −28) have
limited therapeutic viability due to extremely short
half-lives (~1–3 min). Therefore, synthetic somato-
statin analogues (SSAs) have been developed that
provide prolonged activity while maintaining moderate-
or high-affinity binding to various somatostatin receptor
subtypes [2].
The goals of pharmacological treatment for neuro-
endocrine tumours (NETs) are to control symptoms,
induce tumour regression or stabilise tumour growth,
and improve survival. Currently, two long-acting SSAs
(lanreotide Autogel and octreotide LAR) are available
commercially for long-term management of the symptoms
associated with functioning NETs, both of which are
administered once a month and are generally well tolerated
[3]. Treatments used for disease control include interferon
and chemotherapy. Most recently, new drugs such as
everolimus, an oral inhibitor of mammalian target of
rapamycin (mTOR), and sunitinib, a tyrosine kinase
inhibitor, have shown efficacy in controlling NETs, and
in particular, pancreatic NET [4-6].
Recent data suggest that SSAs also have antiproliferative
effects in NET. These effects are mediated directly, by
inhibition of tumour cell proliferation and apoptosis
following receptor activation, and indirectly via inhibitory
effects on mitogenic growth factors (e.g. insulin growth
factor-1 [IGF-1]) and tumour angiogenesis [7,8]. In clinical
studies, SSAs have been shown to stabilise NETs where
proliferation occurs slowly, but tumour regression is
rare [9,10]. Data from a randomised phase III trial in
functioning and non-functioning metastatic midgut
NETs showed that octreotide LAR prolonged time to
tumour progression compared with placebo [11]. While a
large randomised study with lanreotide Autogel versus
placebo in non-functioning NETs completed mid-2013
and results on its antiproliferative effects are due to be
published in late 2013 or early 2014 [12], smaller studies
with lanreotide have shown prolonged stabilisation and,
in several cases, partial responses, thereby indirectly
suggesting antiproliferative effects. This body of evidence
has mostly comprised prospective studies of lanreotide
immediate release [13-16] and microparticles [17-22].
There have also been two recent retrospective studies
of the long-acting depot preparation lanreotide Autogel
[23,24] and an earlier prospective study of lanreotide
Autogel versus microparticles [25].
This is the first prospective study of lanreotide Autogel
to evaluate tumour growth stabilisation (using blindedevaluation) and adverse effects of treatment in patients
with documented progressive NET. It is also one of the
longest prospective evaluations published to date of any
lanreotide formulation for NET treatment.
Methods
Patients
Eligible patients were adults (age >18 years) with a histo-
pathological diagnosis of advanced, well-differentiated
gastroenteropancreatic, bronchopulmonary NET or neu-
roendocrine carcinoma (according to the World Health
Organization classification [26]) and who were not can-
didates for chemotherapy or surgery. Other inclusion
criteria were: measurable disease and disease progression
in the 6 months before study inclusion (defined according
to RECIST 1.0 criteria [27]); grades 0–2 on the Eastern
Cooperative Oncology Group (ECOG) general status
assessment scale; and positive somatostatin receptor
scintigraphy. Patients were excluded if their disease was
suitable for complete surgical resection, had progressed
in the first 6 months after diagnosis, or if they had
bowel obstruction due to a carcinoid tumour. Other
exclusion criteria were: hepatic artery embolisation
or radionucleotide therapy in the preceding 3 months
or scheduled during the study; SSA treatment in the
preceding 6 months; or radiotherapy, chemotherapy
or interferon in the preceding 4 weeks or scheduled
during the study; and comorbid disease that prevented
understanding of and/or compliance with treatment.
Study design and interventions
This study was a multicentre, open-label, phase II trial
(with blinded central radiographic evaluation) conducted
in 17 specialist centres in Spain (see Additional file 1)
between May 2006 and November 2009. The protocol
and amendments, patient information leaflet and informed
consent document were approved by independent ethics
committees at all study centres, and also by the Spanish
Ministry of Health. The trial was conducted in accordance
with the Declaration of Helsinki and Good Clinical Practice
guidelines, and all patients provided written informed
consent. The study is registered with ClinicalTrials.gov
(NCT00326469) and the EU clinical trials register (2004-
002871-18). Protocol amendments implemented after
the study commenced are summarised in (Additional
file 2: Table S1).
Lanreotide Autogel, 120 mg, was administered by deep
subcutaneous injection at baseline and every 28 (±5) days
thereafter by trained study personnel until 23 injections
had been received over ≤92 weeks or until study with-
drawal or death. Concomitant treatments were allowed
at the investigators’ discretion although patients requiring
additional lanreotide Autogel (other than at study visits),
other SSAs, chemotherapy, interferon, radiotherapy, or
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were withdrawn. Patients were also withdrawn if there
was disease progression, adverse events (AEs) deemed
unacceptable, or a major protocol violation.
Assessments and endpoints
Efficacy (radiological, biochemical and clinical) and
pharmacokinetic (PK) assessments were performed every
12 weeks and at the final study evaluation, 28 (±5) days
after the final lanreotide dose. AEs and concomitant
treatments were recorded at each 4-weekly treatment
visit and at the final evaluation.
The primary objective was to assess the efficacy of
lanreotide Autogel on tumour growth stabilisation. The
primary efficacy endpoint was progression-free survival
(PFS), defined as time from study entry to tumour
progression or early death, based on radiographic
scans every 12 weeks (magnetic resonance imaging [MRI]
or computed tomography [CT], depending on disease
location and investigator choice). Radiographic imaging
was assessed by an independent central radiologist who
was blinded to patient identity and imaging test dates.
Secondary efficacy analyses and endpoints included:
factors predictive of PFS and tumour growth control,
defined as time from study entry to last assessment
showing stable disease; response rate (RECIST 1.0);
tumour biomarkers (chromogranin A [CgA] and urinary
5-hydroxyindole acetic acid [5-HIAA]); self-reported NET
symptoms on a 3-point Likert scale; and quality of life
(QoL), assessed using the European Organization for
Research and Treatment of Cancer Quality of Life Ques-
tionnaire (EORTC QLQ)-C30. Metabolic biomarker
(insulin, C-peptide, and gastrin) levels were also pre-
determined secondary efficacy endpoints but data were
collected from too few patients to provide evaluable data
(insulin and C-peptide samples in one patient, gastrin
samples in two). The analytical methodologies and results
are thus not described further in this article.
Safety analyses included AEs (coded using the Medical
Dictionary for Regulatory Activities [MedDRA] version
11.1), vital signs, and serum haematology and biochemistry.
Blood samples for analysis of lanreotide trough serum
levels and, if applicable, for evaluation of the presence
and specificity of anti-lanreotide antibodies were collected
at screening and at weeks 8, 20, 32, 44, 56, 68 and 92,
just before drug administration.
Tumour biomarkers, serum lanreotide concentrations
and anti-lanreotide antibodies were analysed in a central
laboratory. Serum CgA levels were determined using a
radioimmunoassay (RIA) with coefficients of variation (CVs)
of 6–10% (Cisbio International, Gif-sur-Yvette, France),
and urinary 5-HIAA levels were measured using high-
performance liquid chromatography with CVs of 4–6%
(Bio-rad Laboratories GmbH, München, Germany).Circulating lanreotide concentrations were measured
using a validated RIA with [125I]-labelled lanreotide as
a competitor for the quantification of lanreotide [28].
During assay validation, the lower limit of quantification
for lanreotide was 0.078 ng/mL and CVs were 2.3–13.6%.
Anti-lanreotide antibodies were detected using a radio-
immunoprecipitation assay (RIPA) with 1-propranolol
for immune-complex precipitation and [125I]-labelled
lanreotide as the tracer. Results were expressed as the
percentage of precipitation. During validation, the assay
sensitivity was 1/3,200,000 using a rabbit polyclonal anti-
lanreotide antibody and intra- and inter-assay precision
values were <5.7% and <5.3%, respectively. The screening
assay cutpoint was determined as the 95th percentile of
the distribution obtained with pre-treatment samples from
22 patients from the study. Any sample with a percentage
precipitation above the screening cutpoint was subjected
to a confirmatory RIPA in the presence of a large amount
of unlabelled lanreotide (competitor). If the competitor
reduced the response by ≥30%, the serum sample was
considered positive for the presence of anti-lanreotide
antibodies.
Statistical analysis
A sample size of 30 was required based on a minimum
precision of 15.5% for the proportion of patients
progression-free at 1 year and 2 years (assuming that
25% and 12% of patients would be progression-free at
1 year and 2 years, respectively) and an alpha error of 0.05
(bilateral). Accordingly, the estimation error (half-width
of 95% confidence interval [CI]) for the proportion of
patients progression-free at 1 year was planned to be
0.155 and at 2 years was 0.116.
Efficacy and safety analyses were based on data from
all patients who received at least one dose of lanreotide
Autogel (the intention to treat [ITT] and safety popula-
tions, respectively). Kaplan–Meier analysis was used to
determine median (95% CI) PFS time (primary endpoint).
Hazard ratios (HRs) (95% CI) calculated from a stepwise
Cox regression model were used to determine factors
predictive of PFS and tumour growth control, selecting
variables with a significance level of 0.2 for entry in the
model. Variables investigated comprised age, sex, tumour
functionality, time from diagnosis, previous treatment,
initial tumour mass, tumour origin, Ki-67 index, ECOG
scale grade, serum lanreotide concentration and CgA
response. The paired Student’s t-test, or Wilcoxon signed-
rank test if normality assumptions were strongly violated,
was used to assess mean percentage variations from
baseline in biomarkers (CgA, urinary 5-HIAA) and EORTC
QLQ-C30 scores. McNemar’s test was used to ascertain if
variations from abnormal to normal values compared with
baseline for each patient in biomarkers were due to chance
or a trend towards change over time. Statistical analyses
Table 1 Baseline demographic and clinical characteristics
Characteristic Patients (n = 30)
Age, years 63.0 (40–78)
Male, n (%) 15 (50)
Time since diagnosis, years 5.5 (0.2a–22.2)
Prior treatment for NETs, n (%)
Surgery 23 (76.7)
Any systemic antineoplastic therapy 15 (50.0)
Chemotherapyb 10 (33.3)
Interferonb 7 (23.3)
Somatostatin analoguesc 6 (20.0)
Radiotherapyb 1 (3.3)




Small intestine 10 (33.3)




Tumour functionality, n (%)
Functioning 19 (63.3)




Chromogranin A, μg/L 332.5 (44.1–66,056.0)
Urinary 5-HIAA, μmol/d 114.0 (19.9–1684.1)
Ki-67 index
Ki-67 ≤2% 13 (43.3)
Ki-67 >2% 8 (26.7)
Not evaluated 9 (30.0)




Data are median (range) unless stated otherwise for quantitative parameters.
5-HIAA, 5-hydroxyindoleacetic acid; ECOG, Eastern Cooperative Oncology
Group; NETs, neuroendocrine tumours.
aThe patient diagnosed 0.2 years before the study (and thus apparently
non-compliant with inclusion criteria) had had an earlier misdiagnosis (2 years
previously) of vertebral haemangioma that should have been NET metastases.
bPatients who received treatment with radiotherapy, chemotherapy or
interferon within 4 weeks prior to study inclusion or who were scheduled to
receive it during the study were excluded from the study.
cPatients who received treatment with somatostatin analogues within 6
months prior to study inclusion were excluded from the study.
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level was adopted for all tests. Descriptive statistics were
used for all other endpoints.
Results
Patient disposition and baseline characteristics
ITT and safety populations comprised 30 patients (100% of
patients screened). In all, three patients (10.0%) completed
the study and 27 (90.0%) withdrew due to disease
progression (n = 21 [77.8%]), safety reasons (n = 2 AEs
[6.7%] and n = 1 death [3.3%]), major protocol deviation
(n = 2 [6.7%]) or patient choice (n = 1 [3.3%]). Since three
patients withdrew before the first disease evaluation
visit (one died before the first post-baseline visit; two
were subsequently deemed ineligible as one lacked a
histopathological diagnosis and another lacked a positive
octreotide scan), PK evaluation was based on 27 patients.
Patient demographics and clinical characteristics are
presented in Table 1. Median time since diagnosis was
5.5 (range 0.2–22.2) years. Twelve of the 30 patients
(40%) had midgut tumours and eight (27%) had pancreatic
tumours. The majority of tumours were functioning (n = 19
[63%]), almost all of which (n = 18 [95%]) were carcinoid.
Twenty-three patients (77%) had undergone surgery. In
total, 10 patients (33%) had received chemotherapy and
7 (23%) interferon, at least 4 weeks before study entry;
6 (20%) had received SSAs 6 months or more prior to
entering the study. Only one patient had undergone
radiotherapy. Median Ki-67 index was 2.0% (range: 0–20%).
Most (63%) patients presented with good performance
status (i.e. ECOG grade of 0).
Efficacy
Median PFS time was 12.9 months (95% CI: 7.9, 16.5 months)
(Figure 1). The PFS rate at 32 weeks (~7 months) was
69.9% (95% CI: 48.6, 83.7%), at 56 weeks (~13 months)
was 49.7% (95% CI: 29.4, 67.1%), and at 80 weeks
(~18 months) was 24.8% (95% CI: 10.2, 42.8%). By the last
assessment at 92 weeks (~21 months), three (10%) patients
were still progression free.
Ki-67 ranking of individual scores was the only predictive
factor identified in the study population for either PFS
or tumour growth control. Lower Ki-67 ranking predicted
longer PFS (HR: 1.17, 95% CI: 1.03, 1.33; p = 0.02) and
superior tumour growth control (HR 1.10, 95% CI: 0.99,
1.22; p = 0.09), although the latter was not statistically
significant at the 5% level.
Changes in the sum of the longest diameter of target
lesions are shown in Figure 2. None of the patients had
a complete response, one (4%) had a partial response, 24
(89%) exhibited stable disease, and two (7%) experienced
disease progression as their best response.
The proportion of patients in whom CgA normalised/
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Figure 1 Kaplan–Meier plot of PFS among patients treated with
lanreotide autogel (n = 27).
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95% CI: 53.1%, 87.6%; McNemar’s test: p = 0.0002); values
varied from 53% to 67% at subsequent assessments,
remaining significant until week 68 (when CgA was
assessed for only 6 patients). The median decrease from
baseline in CgA concentration was significant after 8 weeks
(−35%; range, –91.8 to −7.8%; Wilcoxon’s test: p < 0.001);
median decreases varied from −31% to −17% at subsequent
assessments, although not all reductions reached statistical
significance. After 8 weeks, in the 19 patients with


















Figure 2 Maximum change in sum of longest diameters of target
NET lesions (n = 27). Each bar represents data for a single patient.in urinary 5-HIAA was −30% (range: –90.4, 24.7%;
paired Student’s t-test: p = 0.0006); median change varied
within −64% to −29% at subsequent assessments but
changes were not all statistically significant.
Of the 19 patients with tumours classified as functioning
based on amine and/or peptide secretions, nine (47%)
had symptoms related to NET at baseline and two
(11%) developed symptoms after starting treatment.
All symptomatic patients reported diarrhoea, one also
experienced asthenia and another reported shortness of
breath and tachycardia; no symptoms were severe. Of the
nine patients who were symptomatic at baseline, five
(56%) achieved complete symptom relief after starting
treatment and three (33%) developed new symptoms
during treatment. One patient had no recorded symptom
evaluation.
EORTC QLQ-C30 scores were generally stable from
baseline to week 56 and showed a non-significant trend
towards improvement across the functional multi-item
scales and the global QoL multi-item scale. The multi-item
symptom scores and single-item scales for adverse effects
showed some fluctuation but were generally stable over the
same period (Additional files 3 and 4: Figures S1a and S1b).
Completed questionnaires were available for fewer than 10
patients after 56 weeks.
Safety and tolerability
Median exposure to study medication was 291 days
(range: 1–702 days). Twenty-five of the 30 patients (83%)
experienced at least one AE; 63% of patients had
treatment-related AEs (Table 2). The most common
treatment-related AEs were diarrhoea (n = 12 [40%]),
asthenia (n = 6 [20%]), flatulence (n = 3 [10%]) and injec-
tion-site pain (n = 3 [10%]). Only one of these AEs was
severe (aerophagia), and another was serious (acute renal
failure) but resolved without sequelae. Three patients
(11%) withdrew due to AEs: these were the aforementioned
serious AE (acute renal failure), a non-serious AE unrelated
to treatment (carcinoid syndrome), and a serious AE
unrelated to treatment (gallbladder fistula; patient later
died). Two patients (7%) died during the study period;
neither death was treatment-related and both were second-
ary to disease progression (one due to intestinal obstruction
and one due to gallbladder fistula).
Pharmacokinetics and immunogenicity
Steady-state levels of lanreotide (5.2 ± 2.0 ng/mL) were
reached at week 20 after five injections. Mean trough
lanreotide levels were broadly stable reaching a maximum
of 6.0 ± 2.9 ng/mL at week 32 (Additional file 5: Figure
S2). After steady-state levels were achieved, lanreotide
serum concentrations were maintained throughout the
92-week treatment period (mean: 5.3 ± 2.0 ng/mL at week
92). At week 8, serum from all 25 patients tested was
Table 2 Patients reporting mild, moderate or severe treatment-related adverse events during treatment with
lanreotide autogel
Organ system Severe Moderate Mild Total
Any 1 (3.3) 8 (26.7) 17 (56.7) 19 (63.3)
Gastrointestinal 1 (3.3) 4 (13.3) 12 (40.0) 13 (43.3)
General and 0 5 (16.7) 9 (30.0) 10 (33.3)
injection site
Neurological 0 0 3 (10.0) 3 (10.0)
Metabolic and nutritional 0 1 (3.3) 1 (3.3) 2 (6.7)
Infections 0 1 (3.3) 0 1 (3.3)
Skin and subcutaneous tissue 0 0 1 (3.3) 1 (3.3)
Ear and labyrinth 0 0 1 (3.3) 1 (3.3)
Renal/urinary tract 0 1 (3.3)a 0 1 (3.3)
Reproductive system and breast 0 0 1 (3.3) 1 (3.3)
Vascular 0 0 1 (3.3) 1 (3.3)
Data are number (%) of patients.
aEvent was serious AE (acute renal failure) but resolved without sequelae.
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assessments, anti-lanreotide antibodies were detected
in two patients (7%), one of them temporarily.
Discussion
The current study provides new evidence for the
antiproliferative effect of long-acting lanreotide Autogel
in NET. In patients with radiologically demonstrated
progressive disease in the previous 6 months, we
showed that lanreotide Autogel, 120 mg every 28 days,
was associated with a median PFS of more than 12 months
as determined by blinded central evaluation. Ki-67 was the
only factor predictive of PFS – such that a lower Ki-67
predicted longer PFS – and there was no deterioration
in QoL during the study. Treatment was generally well
tolerated, with a safety profile consistent with the
pharmacology of the drug.
There is indirect evidence that lanreotide may have
antiproliferative effects on NET. Prospective nonrandom-
ised studies have shown tumour responses or long periods
of tumour stabilisation with the immediate-release [14-16]
and microparticle formulations [17-22]. There have also
been reports of tumour growth control in two long-term
retrospective studies of the long-acting depot (Autogel)
formulation [23,24] and in a randomised study of lanreotide
microparticles versus Autogel over 18 weeks [25]. Fur-
ther evidence showed similar tumour stabilisation with
lanreotide immediate-release, interferon alpha or lanreotide
plus interferon alpha in patients with progressive NET
over 12 months [13]. This offers stronger support for
an antiproliferative effect but lacks a placebo arm for
comparison.
Direct support for an antiproliferative effect in NET
has been reported previously for octreotide LAR, theother commercially available long-acting SSA [11]. In
this randomised, double-blind trial of patients with
non-functioning midgut NETs (the PROMID study), the
time to tumour progression was significantly longer in
patients receiving octreotide LAR than in those receiving
placebo (14 and 6 months, respectively) when hepatic
tumour burden was ≤10%. Although between-study
comparisons should be made with caution, PFS and
disease stabilisation were similar in PROMID and the
current study despite key differences in study design.
In our study, for example, patients had more advanced
disease, had previously received systemic treatments,
and had pancreatic, intestinal or lung NETs, while in
PROMID the population was limited to those with midgut
NETs. A particular strength of our study is that all
participants had documented progressive disease within
the previous 6 months whereas the proportion with
disease progression at enrollment is not reported for
PROMID. On the other hand, PROMID was a placebo-
controlled study, while ours was not. Data from two
large, ongoing, randomised, double-blind, placebo-
controlled studies with lanreotide Autogel are thus awaited
with interest. The first was conducted in a homogeneous
population of patients with non-functioning gastroentero-
pancreatic NETs (CLARINET study: NCT00353496) [12]
and the second in patients with a history of carcinoid
syndrome (ELECT study: NCT00774930) [29]. Data from
these studies are expected late 2013 or early 2014.
Other treatment modalities that have shown promise as
antiproliferative agents for advanced NET include mTOR
or tyrosine kinase inhibitors. Recent clinical trials have
demonstrated that these molecular targeted therapies can
provide tumour stabilisation in patients with advanced
pancreatic NET (PFS of 11.0 months for everolimus and
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everolimus and octreotide LAR also stabilised tumour
growth in patients with carcinoid NET [32]. To date, some
preliminary research with octreotide and lanreotide in
various NET types has suggested that combination therapy
with molecular targeted therapies may provide antiproli-
ferative effects that take advantage of potential synergies
between these agents’ different modes of action [4-6].
No unexpected safety signals were noted, which is
consistent with other recent lanreotide studies in patients
with NET [23,24]. The most common AEs were primarily
gastrointestinal and asthenia, and the AEs observed
did not lead to a higher than anticipated incidence of
treatment-related withdrawal.
Lanreotide trough serum concentrations remained
stable for the duration of this study suggesting sustained
exposure to lanreotide Autogel for at least 92 weeks.
Lanreotide treatment also exhibited limited immuno-
genicity, as only two patients developed antibodies (in
one case, temporarily). Therefore, there is low risk
that antibodies might adversely affect efficacy, safety
or pharmacokinetics.
This study has several limitations. First, as noted earlier,
it was a single-arm (and thus unblinded) study in a
relatively small population of patients with functioning
or non-functioning progressive NETs of different origins.
While the finding of substantial antiproliferative efficacy
is promising, data from the CLARINET study are expected
to corroborate findings. Second, the study was not
powered sufficiently to assess potential predictive
factors, nor did it assess hepatic involvement and its
effect on PFS. Third, the exclusion from our study of
patients with disease progression in the 6 months following
diagnosis likely excluded those with more aggressive
disease and could have biased the results towards longer
PFS. However, in the RADIANT 1–3 studies [30,32,33],
where such patients were not excluded, those whose
tumors progressed within 6 months of diagnosis repre-
sented <4%, <14% and <9% of the respective study pop-
ulations. It is therefore unlikely that more than a few
cases of more aggressive disease were excluded from
our study and, as such, it is unlikely that this affected
the results. Finally, a full PK profile was not assessed
but will be determined from the phase III studies of
lanreotide and used in population PK studies.
Conclusions
These findings show that lanreotide Autogel achieved
clinically meaningful PFS (>12 months) in patients with
radiologically confirmed progressive, well-differentiated
NETs, strongly supporting an antiproliferative effect.
Lanreotide also provided symptom control with stable
QoL, and a favourable tolerability profile. These findings
are encouraging, particularly in this group of patients withlimited treatment options. In addition to future clinical
trials of lanreotide Autogel for NET stabilisation, further
research on treatment strategies that combine lanreotide
and molecular targeted therapies will help characterise
the clinical utility of lanreotide-based combinations in
the management of NETs.
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